- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07574489
Whole Versus Partial Gland Boost During Prostate SBRT
Whole Versus Partial Gland Boost During Prostate SBRT (Gland Boost)
The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is a phase 2 randomized clinical trial evaluating two dose escalation strategies during prostate stereotactic body radiotherapy (SBRT). A total of 160 patients with prostate adenocarcinoma will be enrolled and randomized in a 1:1 ratio to one of two treatment arms.
160 patients will be enrolled in this study over 3.2 years. Eligible participants will be stratified by risk group and tamsulosin use and randomized to one of two treatment arms. Both arms will receive 3625 cGy to the prostate plus planning margin delivered over 5 fractions. Arm A will receive an additional boost of 4000 cGy to the prostate alone. Arm B will receive an additional boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Acute and chronic GU and GI toxicities will be measured, as well as biochemical progression-free survival. Toxicities will be measured using CTCAE, Radiation Therapy Oncology Group, and Expanded Prostate Cancer Index Composite domains.
Participants will be followed for up to 5 years after completion of treatment.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Krishna Gottipati, MS
- Numéro de téléphone: 4025593518
- E-mail: krgottipati@unmc.edu
Sauvegarde des contacts de l'étude
- Nom: IIT Office Gottipati
- Numéro de téléphone: 4025590963
- E-mail: IITOFFICE@unmc.edu
Lieux d'étude
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68198
- Fred & Pamela Buffet Cancer Center
-
Contact:
- Michael Baine, MD, PhD
- Numéro de téléphone: (402) 552-2703
- E-mail: mbaine@unmc.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults ≥19 years of age
- Patients with a diagnosis of prostate adenocarcinoma for whom SBRT to the prostate +/- proximal seminal vesicles is being offered
- Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities, including MRI or CT scan
- PI-RADS 4 or 5 lesion seen on pretreatment MRI
- IPSS/AUA (Appendix D, E) symptom score less than 16
Exclusion Criteria:
- Prior treatment for prostate cancer
- Prior solid cancer diagnosis in the last 5 years
- Any history of anal or rectal cancer
- Any history of invasive carcinoma of the bladder
- History of prior circumferential resection of the rectum (such as LAR or APR)
- History of inflammatory bowel syndromes not adequately controlled on current medication regimen
- Urinary or fecal incontinence or chronic diarrhea requiring more than 1 pad per day
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Arm A: boost to prostate alone
Participants assigned to Arm A will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4000 cGy to the clinical target volume (CTV), consisting of the prostate alone without a margin. Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB). |
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost |
|
Expérimental: Arm B: boost to dominant intra-prostatic lesion (DIL)
Participants assigned to Arm B will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB). |
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Grade 2 or Higher Acute Genitourinary Toxicity
Délai: From end of treatment to 3 months post-treatment
|
To evaluate acute genitourinary (GU) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using Common Terminology Criteria for Adverse Events Version 6.0 (CTCAE) |
From end of treatment to 3 months post-treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Grade 2 or Higher Acute Gastrointestinal Toxicity
Délai: From end of treatment to 3 months post-treatment
|
To evaluate gastrointestinal (GI) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using CTCAE |
From end of treatment to 3 months post-treatment
|
|
Biochemical Progression-Free Survival
Délai: From initiation of study treatment to 5 years post-treatment
|
Time from initiation of study treatment to biochemical disease progression or death from any cause |
From initiation of study treatment to 5 years post-treatment
|
|
Chronic Gastrointestinal Toxicity - Cumulative Incidence
Délai: From 6 months to 21 months post-treatment
|
Cumulative incidence of chronic gastrointestinal (GI) toxicities assessed using CTCAE, Radiation Therapy Oncology Group (RTOG), and Expanded Prostate Cancer Index Composite (EPIC) domains. |
From 6 months to 21 months post-treatment
|
|
Chronic Genitourinary Toxicity - Cumulative Incidence
Délai: From 6 months to 21 months post-treatment
|
Cumulative incidence of chronic genitourinary (GU) toxicities assessed using CTCAE, RTOG, and EPIC domains. |
From 6 months to 21 months post-treatment
|
|
Chronic Gastrointestinal Toxicity
Délai: At 5 years
|
To evaluate chronic GI toxicities at 5 years using CTCAE, RTOG, and EPIC domains. |
At 5 years
|
|
Chronic Genitourinary Toxicity
Délai: At 5 years
|
To evaluate chronic GU toxicities at 5 years using CTCAE, RTOG, and EPIC domains. |
At 5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Michael Baine, MD, PhD, University of Nebraska medicine
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Gland Boost
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .